Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HECN30227 injection(SAD)
HECN30227 · 1 trial · 1 indication
A summary of adverse events, including Serious Adverse Events(SAEs)
A summary of adverse events, including Serious Adverse Events(SAEs)
| Arm | Type | Description |
|---|---|---|
| HECN30227 50~800 mg | EXPERIMENTAL | - |
| HECN30227 100~400 mg | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HECN30227 injection(SAD) | DRUG | single subcutaneous administrations |
| Placebo(MAD) | DRUG | 0.9% Sodium Chloride Injection |
| Placebo(SAD) | DRUG | 0.9% Sodium Chloride Injection |
| HECN30227 injection (MAD) | DRUG | multiple subcutaneous administrations |
Inclusion Criteria: 1. Subjects must understand and comply with the study procedures, voluntarily participate, and sign the informed consent form. 2. Male subjects must weigh at least 50 kg; female subjects must weigh at least 45 kg. 3. Vital signs, physical examination, laboratory tests, electroca...
Top 20 of 28 competitors
HECN30227 is an investigational small molecule being developed for the treatment of HBV infection, specifically chronic hepatitis B. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
HECN30227 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SBFM. The company is conducting clinical trials for this investigational drug candidate.
HECN30227 is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The ongoing Phase 1 trial is recruiting participants to evaluate the drug's safety and tolerability.
HECN30227 is being evaluated in a Phase 1 clinical trial registered as NCT07771140. This randomized, double-blind, controlled study is recruiting healthy subjects and subjects with chronic hepatitis B in China, with a planned enrollment of 78 participants.
Yes, HECN30227 is also known as HECN30227 injection(SAD). The alternative name refers to the single ascending dose formulation of the drug being tested in the Phase 1 clinical trial.